584.99CHF+1.00%Mkt Cap: —P/E: 14.821d ago
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value50.82B $
Revenue (TTM)7.84B $
Gross Profit2.91B $
Net Income (TTM)1.23B $
Revenue/Share112.22 USD
Last Price584.99 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.1K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)14.82
P/E (Forward)—
PEG—
EV/EBITDA18.63
EV/Revenue6.48
P/S—
P/B5.03
EPS (TTM)39.52
EPS (Forward)—
52W Range
560.2089% of range588.20
52W High588.20 CHF
52W Low560.20 CHF
Profitability
Gross Margin37.14%
Oper. Margin23.41%
EBITDA Margin34.78%
Profit Margin-1.60%
ROE12.90%
ROA5.44%
Growth
Revenue Growth11.20%
Earnings Growth39.20%
Cash Flow & Leverage
Operating CF1.64B $
CapEx (TTM)—
FCF Margin-22.81%
FCF Yield—
Net Debt4.20B $
Net Debt/EBITDA1.54
Balance Sheet
Debt/Equity51.12
Current Ratio1.66
Quick Ratio0.59
Book Value/Sh116.37 CHF
Cash/Share6.980 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate5.000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.74.43M
Float69.74M
Insiders0.09%
Institutions61.72%
Technical
SMA 50424.03 (+38.0%)
SMA 200436.80 (+33.9%)
Beta0.84
S&P 52W Chg18.16%
Avg Vol (30d)15.12K
Avg Vol (10d)76.48K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—